Moderna Beats Revenue Estimates on Strong COVID Sales, but Shares Drop on Norovirus Setback

Moderna reported $145M Q2 revenue, beating $103M estimates on strong COVID vaccine sales. Shares fell after norovirus vaccine missed key trial goal.